

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

---

**FORM 8-K**

---

**CURRENT REPORT  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): June 16, 2022**

---

**PLIANT THERAPEUTICS, INC.**

(Exact name of Registrant as Specified in Its Charter)

---

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**001-39303**  
(Commission  
File Number)

**47-4272481**  
(IRS Employer  
Identification No.)

**260 Littlefield Avenue,  
South San Francisco, CA**  
(Address of Principal Executive Offices)

**94080**  
(Zip Code)

**Registrant's Telephone Number, Including Area Code: (650) 481-6770**

**Not Applicable**

(Former Name or Former Address, if Changed Since Last Report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value \$0.0001 per share	PLRX	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

**Item 5.07. Submission of Matters to a Vote of Security Holders.**

Pliant Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”) on June 16, 2022. As of April 20, 2022, the record date for the Annual Meeting, there were 36,169,468 shares of the Company’s common stock outstanding and entitled to vote at the Annual Meeting. The Company’s stockholders voted on the following matters, which are described in detail in the Company’s Definitive Proxy Statement filed with the U.S. Securities and Exchange Commission on April 29, 2022: (i) to elect John Curnutte, M.D., Ph.D. and Smital Shah as Class II directors of the Company to serve for a three-year term expiring at the Company’s 2025 Annual Meeting of Stockholders and until his successor has been elected and qualified (“Proposal 1”), (ii) to approve, by non-binding advisory vote, the resolution approving the compensation of the Company’s named executive officers (“Proposal 2”), (iii) to elect, by non-binding advisory vote, the frequency of future non-binding advisory votes on resolutions approving named executive officer compensation (“Proposal 3”) and (iv) to ratify the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for its fiscal year ending December 31, 2022 (“Proposal 4”).

**Proposal 1:** The Company’s stockholders approved the election of the aforementioned Class II directors recommended for election at the Annual Meeting. The Company’s stockholders voted for the Class II directors as follows:

Nominee	For	Withhold
John Curnutte, M.D., Ph.D.	22,717,060	5,291,923
Smital Shah	22,748,022	5,260,961

The broker non-votes for Proposal 1 totaled 6,124,917 shares of common stock.

**Proposal 2:** The Company’s stockholders approved, by non-binding advisory vote, the compensation of the Company’s named executive officers, as follows:

For	Against	Abstain
27,888,784	111,574	8,625

The broker non-votes for Proposal 2 totaled 6,124,917 shares of common stock.

**Proposal 3:** The Company’s stockholders approved by non-binding advisory vote, the frequency of future non-binding advisory votes on resolutions approving named executive officer compensation, as follows:

ONE YEAR	TWO YEARS	THREE YEARS	ABSTAIN
27,954,029	29,118	21,831	4,005

**Proposal 4:** The Company’s stockholders ratified the selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm. The votes cast at the Annual Meeting were as follows:

For	Against	Abstain
34,121,601	6,315	5,984

No other matters were submitted to or voted on by the Company’s stockholders at the Annual Meeting.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

PLIANT THERAPEUTICS, INC.

Date: June 17, 2022

By: /s/ Keith Cummings  
Keith Cummings, M.D., MBA  
Chief Financial Officer